Dr Gilada added that if a particular patient is already resistant to dolutegravir, which has a high genetic barrier to developing drug resistance, he/she will be given the same failing regimen for a year, thus exposing his/her sexual contacts to HIV infection and that too with a Dolutegravir resistance strain.